Free tool
FAERS Monitor: Tukysa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213411 or its brand name (Tukysa, Tucatinib). Reports on generic versions are filed under their own applications.
Reports
7,107
Serious
4,642
65% of reports
Hospitalization
1,944
Death reported
729
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea1,803
- fatigue980
- nausea941
- vomiting533
- off label use481
- death472
- malignant neoplasm progression455
- palmar-plantar erythrodysaesthesia syndrome418
- product dose omission issue377
- asthenia371
- decreased appetite323
- disease progression306
- metastases to central nervous system305
- dehydration276
- neoplasm progression260
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 9 |
| 2020 | 797 |
| 2021 | 1,356 |
| 2022 | 974 |
| 2023 | 931 |
| 2024 | 1,684 |
| 2025 | 765 |
| 2026 | 587 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,052 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| metastases to central nervous systemSignal | 305 | 71.7 | 64.1 | 20,690 |
| palmar-plantar erythrodysaesthesia syndromeSignal | 418 | 54.0 | 49.2 | 21,332 |
| neoplasm progressionSignal | 260 | 22.3 | 19.8 | 5,236 |
| malignant neoplasm progressionSignal | 455 | 13.2 | 12.1 | 5,122 |
| diarrhoeaSignal | 1,803 | 8.3 | 8.0 | 11,877 |
| disease progressionSignal | 306 | 7.7 | 6.9 | 1,774 |
| dehydrationSignal | 276 | 6.1 | 5.5 | 1,186 |
| decreased appetiteSignal | 323 | 4.1 | 3.7 | 767 |
| product dose omission issueSignal | 377 | 3.8 | 3.4 | 784 |
| fatigueSignal | 980 | 3.7 | 3.5 | 2,027 |
| nauseaSignal | 941 | 3.5 | 3.3 | 1,761 |
| vomitingSignal | 533 | 3.4 | 3.1 | 899 |
| astheniaSignal | 371 | 2.9 | 2.6 | 475 |
| off label use | 481 | 1.6 | 1.5 | 120 |
| death | 472 | 1.6 | 1.5 | 117 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.